Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 7, 1996, Pages 2607-2612

  Ohta, Kazuyasu ^a   Pang, Xuan Ping ^a   Berg, Loretta ^a   Hershman, Jerome M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL COUNT; CELL PROLIFERATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CATTLE; CELL DIVISION; CELL LINE; CYTOKINES; DNA; HUMANS; INTERFERON TYPE II; INTERLEUKIN-1; IODIDES; RATS; THYROID NEOPLASMS; THYROTROPIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029984163     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.7.2607     Document Type: Article

References (26)

1. Mazzaferri EL. 1991 Carcinoma of follicular epithelium. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid, 6th ed. Philadelphia: Lippincott; 1138-1165.
2. Simpson WJ, Mckinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T. 1987 Papillary and follicular thyroid cancer-prognostic factors in 1578 patients. Am J Med. 83:479-488.
3. Cunningham MP, Duda RB, Recant W, Chimiel JS, Sylvester J, Fremgen A. 1990 Survival discriminates for differentiated thyroid cancer. Am J Surg. 160:344-347.
4. Tubiana M, Schlumberger M, Rougier P, et al. 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 55:794-804.
5. Thoresen SO, Akslen LA, Glattre E, Haldorsen T, Lund EV, Schoultz M. 1989 Survival and prognostic factors in differentiated thyroid cancer-a multivariate analysis of 1,055 cases. Br J Cancer. 59:231-235.
6. McConahay WM, Hay ID, Woolner LB, Van Heerden, Taylor WF. 1986 Papillary thyroid cancer treated at the Mayo Clinic, 1446 through 1470: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 61:978-946.
7. De Keyser LFM, Van Herle A. IWS Differentiated thyroid cancer in children. Head Neck Surg. 8:100-104.
8. Pang X-P, Ross NS, Park M, Juillard GJF, Stanley TM, Hershman JM. 1992 Tumor necrosis tactor-α activates nuclear factor kappa B and induces manganous Superoxide dismutase and phosphodiesterase mRNA in human thyroid carcinoma cells. J Biol Chem. 267:12826-12830.
9. Yip I, Pang X-P, Berg L, Hershman JM. 1945 Antitumor actions of interferon-γ and interleukin-1β on human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 80:1664-1669.
10. Pang X-P, Yoshimura M, Wang J, Dubinett SM. 1994 TNF-α induced anti-proliferation is not dependent on the autocrine action of TGF-β1 in a human thyroid cancer line. Lymphokine Cytokine Res. 13:93-97.
11. Kimura H, Yamashita S, Namba H, et al. 1992 Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab. 75:596-602.
12. Usa T, Tsukazaki H, Namba H, et al. 1994 Correlation between suppression of c-myc and antiproliferative effect of transforming growth factor-β1 in thyroid carcinoma cell growth. Endocrinology. 135:1378-1384.
13. Pang X-P, Hershman JM, Chung M, Pekary AE. 1989 Characterization of tumor necrosis factor-α receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Fndocrinology. 125:1783-1788.
14. Lu C, Kasagi K, Hidaka A, Hatabu H, Iida Y, Konishi J. 1940 Simultaneous measurement of TSH binding inhibitor immunoglobulin and thyroid stimulating autoantbody activities using cultured FRTL-5 cells in patients with untreated Craves' disease. Acta Endocrinol (Copenh). 123:282-290.
15. Chomczynski P, Sacchi N. 1987 Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:156-159.
16. Magnusson RP, Chazenbalk GD, Gestautas J, et al. 1987 Molecular cloning of the complementary deoxyribonucleic acid for human thyroid peroxidase. Mol Endocrinol. 1:856-861.
17. Nagayama Y, Kaufman KD, Seto P, Rapoport B. 1989 Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun. 165:1184-1140.
18. Ohta K, Endo T, Onaya T. 1490 The mRNA levels of thyrotropin receptor, thyroglobulin, and thyroid peroxidase in neoplastic human thyroid tissues. Biochem Biophys Res Commun. 165:1184-1190.
19. Clark MA, Chen MJ, Crooke ST, Bomalaski JS. 1988 Tumor necrosis factor (cachectin) induces phopholipase A2-activating protein in endothelial cells. Biochem J. 250:125-132.
20. Neale ML, Fiera RA, Matthews N. 1988 Involvement of phospholipase A2 activation in tumor cell killing by tumor necrosis factor. Immunology. 64:81-85.
21. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. 1989 Prolonged activation of jun and collagenase gene by tumor necrosis factor-alpha. Nature. 337:661-663.
22. Zang YH, Lin JX, Yip YK, Vilcek J. 1988 Enhancement of cAMP levels and of activity by tumor necrosis factor and interleukin 1 in human fibroblast: role in the induction of interleukin 6. Proc Natl Acad Sci USA. 85:6802-6805.
23. Marino MW, Preffer LM, Guidon Jr PT, Donner DB. 1989 Tumor necrosis factor induces phosphorylation of a 28 kDa mRNA cap-binding protein in human cervical carcinoma cells. Proc Natl Acad Sci USA. 86:8417-8421.
24. Longstreet M, Miller B, Howe PH. 1492 Loss of transforming growth factor beta 1-induced growth arrest and p34 regulation in ras-transfected epithelial cells. Oncogene. 7:1594-1556.
25. Reiss M, Velucci VF, Zhou ZL. 1993 Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes. Cancer Res. 53:899-904.
26. Schroy JP, Rifkin RJ, Coffey S, Winawer E, Fridman E. 1990 Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylane bisacamide. Cancer Res. 50:261-265.